1.- La ingestión de aguas minerales bicarbonatadas sódicas con diferentes concentraciones de minerales no

CONCLUSIONES 1.- La ingestión de aguas minerales bicarbonatadas sódicas con diferentes concentraciones de minerales no aumenta la PA en pacientes mayores con HTA grado I 2.- El grado de mineralización del agua y el aumento de la PA muestran una relación inversa, ya que las mayores concentraciones de bicarbonato sódico, calcio, potasio y magnesio, tienen un efecto protector contra el aumento de PA al final del periodo de intervención, con efectos independientes de la PA y de la excreción de minerales urinarios al inicio del estudio. 3.- Nuestros datos confirman que la sensibilidad de la PA al cloruro sódico, depende de ambos, sodio y cloruro, y que la ingesta de sales no cloradas de sodio, como el bicarbonato sódico no sólo presenta un efecto menor que el cloruro sódico sobre la PA, sino que protege contra su elevación. 4.- Los estudios epidemiológicos y clínicos sugieren que la dietas bajas en potasio o calcio amplifican el efecto de la ingesta elevada de cloruro sódico en la presión arterial. Los resultados de nuestro estudio confirman estos datos y muy probablemente esos cationes presentes en las aguas minerales en cantidades no despreciables potencien los efectos del bicarbonato. Por ello un control más riguroso sobre el balance ionico podria ser beneficioso para los hipertensos. 5.- La ingesta de aguas bicarbonatadas sódicas disminuyó la excreción urinaria de calcio, factor añadido claramente beneficioso en la población mayor hipertensa predominantemente femenina, con riesgo de osteoporosis.

BIBLIOGRAFIA BIBLIOGRAFIA 1. Staessen JA; Wang J; Bianchi WH;. Essential hypertension. Lancet. 2003 May 10;361(9369):1629-41 2. Banegas JR; Rodriguez-Artalejo F. El problema de la hipertension arterial en España. Rev Clin Esp 2002; 202: 12-5

3. Banegas JR; Rodríguez-Artalejo F; Ruilope LM; Graciano A; Luque M; de la Cuz-Troca JJ; Garcia-Robles R; Tamargo J; Rey-Calero J. Hypertension magnitude and management in the elderly population of Spain. J Hypertension. 2002;20(11):2157-64 4.Birkenhäger WH, Reid JL,. Handbook of hypertension. Volume 6. Epidemiology of hypertension. Amsterdam: Elsevier; 1985. 5. Sans S, Kesteloot H, Kromhout D on behalf of the Task Force of the European Society of Cardiology on cardiovascular mortality and morbidity statistics in Europe. The burden of cardiovascular diseases mortality in Europe. Eur Heart J 1997;18:1231-48. 6. Luque M, editor. Factores de riesgo cardiovascular. Madrid: Fundación Ciencia y Medicina; 1995. 7. Banegas JR, Rodríguez Artalejo F, Graciani A, Villar F, Guallar P, Cruz JJ. Epidemiología de la hipertensión arterial en España. Prevalencia, conocimiento y control. Hipertensión 1999;16:315-22. 8. Fenández JM, Coca A, Aranda P, et al. La hipertensión arterial en España. Madrid: B&F Gestión y Salud; 1999. 9. Coca A. Control de la hipertensión arterial en España. Resultados del estudio Controlpres 95. Hipertensión 1995;12:182-8. 10. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del Estudio Controlpres 98. Hipertensión 1998;15:298-307. 11. Coca A.; De la Sierra A. Decisiones clinicas y terapeuticas en el paciente hipertenso. Editorial Jims, 3ª edicion revisada, 2004 12. Khattar RS; Swales JD; Dore C. Effect of aging on the prognostic significance of ambulatory systolic, diastolic, and pulse pressure in essential hypertension. Circulation 2001;104:783-89 13. Vasan RS; Larson MG; Leip EP; et al. Assessment of frequency of progression too hypertension in non-hypertensive participans in the Framingham Heart Study: a cohort study. Lancet 2001;358:1682-86 14. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13 15. López Fernández V, Peña Luengo LA, Iglesias Heredero A, Herrero Puente P, Vázquez Álvarez J, Suárez García S, ÁlvarezCosmea A, Prieto Díaz MA, Marín Iranzo R. Prevalencia de la hipertensión arterial sistólica aislada en una población mayor de 60 años. Hipertensión 2002;19(9):384-9. 16. Benetos A; Zureik M; Morcet J; Thomas F; Bean K; Safar M. A decrease in diastolic blood pressure combined with an increase in systolic blood presure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000;35: 673-80 17. Pickering G. Hypertension. Definition, natural histories and consequences. Am J Med 1972;52:570-83 18. 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. Journal of Hypertension 2003; 21: 1011-1053 19. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JNC 7- Complete Version. Hypertension. 2003; 42:1206-1252.

20. Ministerio de Sanidad y Consumo/Sociedad Española de Hipertensión-Liga Española para la Lucha contra la hipertensión arterial. Control de la Hipertensión Arterial en España, 1996. Madrid: Idepsa; 1996 21. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-242 22. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial. Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002. Hipertensión 2002; 19 ( supl 3, mayo). 23. González-Juanatey JR, Mazón Ramos P, Soria Arcos F, Barrios Alonso V, Rodríguez radial L, Bertomeu Martínez V. Actualización (2003) de las Guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol 2003; 56: 487-497 24. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983 1992 25. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. European Journal of Cardiovascular Prevention and Rehabilitation 2003. 10 (suppl 1) 26. Marin R; de la Sierra A; Armario P; Campo C; Banegas JR; Gorostide M. Guia sobre el diagnostico y tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc).2005;125:24-34 27. Anderson KM; Wilson PW; Odell PM; Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62 28. Conory RM; Pyörälä K; Fitzgerald AP; Sans S; Menotti A; De Backer G et al on behalf of the SCORE project group. Predition of ten-year risk of fatal cardiovascular disease in Europe; the SCOPE project, Eur Heart J 2003. 29. Carretero OA; Oparil S. Essential hypertension. Circulation 2000 ;101 : 329-35 30. Kaplan N. Hipertension clinica.waverly Hispanica, 4ª edicion.2003 :357-511 31. Listerri JL ; Rodriguez G ; Alonso FJ ; Lou S ; Division JA ; Santos JA et al. Control de la presion arterial en la población hipertensa española atendida en atención primaria. Estudio PRESCAP 2002. Med Clin (Barc) 2004;122:165-71 32. Coca A. Evolución del control de la hipertensión arterial en Atención Primaria en España. Resultados del estudio Controlpres 2003, Hipertensión 2005;22 33. Abanades JC; Diaz S; de la Figuera M; Taboada M; Palancar JM; Vinioles E. Hipertensión Arterial. Programas basicos de salud nº 1 Programa del adulto. Madrid: Doyma; 1997:11-52 34. De la Figuera M; Dalfo A. Hipertensión Arterial. Martin Zurro. Atención primaria. Conceptos, organización y practica clinica. Elservier 5ª edicion 2003:764-98 35. Molina Núñez M, Rabadán Rubio JA. Manual básico de nefrología para Atención Primaria. La Gráfica, 2000 36. Klungel OH; de Boer A; Paes AHP et al. Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatement, and control of hypertension. Am J Hypertens 2000;13:88-91

37. Beevers G; Lip GYH; O Brien E. Blood pressure measurement. Part I-Sphygmomanometry: factors common to all techniques. BMJ 2001a;322:981-85 38. Schwartz GL; Turner ST; Moore JH; Sing CF. Effect of time of day on intraindividual variability in ambulatory blood presure. Am J Hypertens 2000;13:1203-09 39.Villar C, García-Puig J, Martínez MA, Aguirre A, Sánchez M, Nevado A. Determinación de la presión arterial por médico o enfermera: relación con la presión ambulatoria y la masa del ventrículo izquierdo. Med Clin (Barc) 1999;113:770-4 40. De la Sierra A; Bové A; Sierra C; Bragulat E; Gómez-Angelats E; Antonio M; Larrousse M; Coca A. Impacto de los componentes y sistemas de medición de la presión arterial sobre la lesión de órgano diana y las complicaciones cardiovasculares en la hipertensión arterial. Med Clin (Barc) 2002;119(4):125-9 41. O Brien E; Asmar R; Beilin L; Imai Y; Mancia G; Mengden T et al on beahalf of the European Society of hypertension Working Group on Blood Pressure Monitoring. European Society of hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003;21:821-48 42. O Brien. Medicion de la tension arterial. ABC de la Hipertensión. Ancora S.A.;1996:1-34 43. Aylett M; Marples G; Jones K; Rhodes D. Evaluation of normal and large sphygmomanoter cuffs using the Omron 750CP. J Hum Hypertens 2001;15:131-34 44. Bakx C; Oerlemans G; van den Hoogen H et al. The influence of cuff size on blood pressure measurement. J Hum Hypertens 1997;11:439-45 45. Clausen LR; Olsen CA; Olsen JA et al. Influence of cuff size on blood pressure among schoolchildren. Blood Pressure 1999;8:172-76 46. Kaplan N. Hipertension clinica.waverly Hispanica, 4ª edicion.2003:25-56 47. Netea RT; Lenders JWM; Smits P; Thien T. Arm position is important for blood pressure measurement. J Hum Hypertens 1999;13:105-09 48. Verdecchia P; Angeli F; Gattibigio R. Clinical usefulness of ambulatory blood pressure monitoring. J Am Soc Nephrol. 2004;15:S30-3 49. Kikuya M; Ohkubo T; Asayama K; Metoki H; Obara T; Aito S,et al. Ambulatory blood pressure and 10-year risk of cardiovascular and non cardiovascular mortality. The Osahama study. Hypertension. 2005;45:240-5 50. O Brien E; Asmar R; Beilin L; Imai Y; Mancia G; Mengden T, et al. Practique guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:679-701 51. Korokoff NS. On methods of studying blood pressure. St Petersburg: Bull Imperial Mil Med Avad; 1905 52. Grim CM; Grim CE. A curriculum for the training and certification of blood pressure measurement for health care providers. Can J Cardiol 1995;11(Suppl.H):38H-42H

53. O Brien E. Blood pressure measurement is chaging!. Heart 2001;85:3-5 54. Bobrie G; Chatellier G; Genes G; Clerson P; Vaur L, et al. Cardiovascular prognosis og masked Hypertensyon detected by blood pressure selfmeasurement in elderly treted hypertensive patients. JAMA.2004;291:1342-9 55. Hond ED; Celis H; Fagard R; Kearly L; Leeman M; O Brien E, et al. Self measuremente versus ambulatory blood pressure in the diagnosis of hypertension. J Hypertens. 2003;21:717-22 56. Stergiu G; Skeva I; Baibas N; Kalkana CH; Roussias L; Mountokakalis TH. Diagnosis of hypertension using home or ambulatory blood pressure monitoring: comparison with the conventional strategy based on repeated clinic blood pressure measurements. J Hypertens 2000;18:1745-51 57. Asmar R; Zancheti A. Guidelines for the use of self blood pressure monitoring: a summary report of the first international consensus conference. J Hypertens. 2000;18:493-508 58. Sociedad Española de Hipertension y Liga Española para la Lucha contra la Hipertension Arterial (SEHLELHA). Guia Española de Hipertensión Arterial 2005. Hipertensión. 2005;22 Supl 2:16-26 59. Staessen JA; Den Hond E; Celis H; Fagard R; Keary L; Vandenhoven G, et al. Antihypertensive treatment base don blood pressure measurement at home or in the physician s office: a randomized controlled trial. Jama 2004;291:955-64 60. Cappuccio FP; Kerry SM; Forbes L; Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ.2004;329:145-56 61. Verdecchia P. Prognostic value of ambulatory blood pressure. Hypertension 2000;35:844-51 62. Pickering TG. Blood pressure monitoring outside the office for the evluation of patiens with resistant hypertension. Hypertension 1988;11 Supl 2:96-100 63. Yarows SA; Julius S; Pickering TG. Home blood pressure monitoring. Arch Intern Med 2000;160:1251-57 64. Association for the Advancement of Medical Instrumentation: American National Standard: electronic or automated sphygmomanometers. Arlington, VA, AAMI,1993. 65. American College of Physicians: Automated ambulatory blood pressure and self-measured blood pressure monitoring devices: their role in the diagnosis and management of hypertension. Ann Intern Med 1993; 118: 889-892. 66. Verdecchia P. Using out of office blood pressure monitoring in the management of hypertension. Curr Hypertens Rep 2001;3:400-05 67. O Brien E; Coast A; Owens P, et al. Use and interpretation of ambulatory blood pressure monitoring: Recommendations of the British Hypertension Society. BMJ 2000;320:1128-34 68. Villar J; Stiefel P; Miranda ML. Otros parámetros de utilidad en el tratamiento del paciente con hipertensión arterial. Med Clin (Barc) 2002;119(11):423-8 69. Kaplan N. Hipertension clinica.waverly Hispanica, 4ª edicion.2003:56-121

70. Page IH. The nature of arterial hypertension. Arch Intern Med 1963;111:103-15 71. Turner ST; Boerwinkle E. Genetics of hypertension, target-organ complications, and response to therapy. Circulation 2000;102 Supl 4:IV44-5 72. O Shaughnessy KM. The genetics of essential hypertension. Br J Clin Pharmacol 2001;51:5-11 73. Rebbeck TR; Turner ST; Sing CF. Probanility of having hypertension. J Clin Epidemiol 1996;49:727-34 74. Fuentes RM; Notkola I-L; Shemeikka S.et al. Familial agregation of blood pressure. J Hum Hypertens 2000;14:441-45 75. Williams RR; Hunt SC; Heiss G; et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (The Health family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 2001;87:129-35 76. Dominiczak AF; Negrin DC; Clark JS; et al. Genes and hypertension. Hypertension 2000 ;35 :164-72 77. Swales JD. Overview of essential hypertension. Textbook of hypertension. Oxford:Blackwell Science;1994:655-60 78. Giner V; Corella D; Chaves FJ; Pascual JM; Portoles O; Marin P; Lozano JV; Armengod ME; Redon J. Polimorfismos genéticos del sistema reninaangiotensina e hipertensión arterial esencial en la población española. Med Clin (Barc) 2001; 117: 525-529 79. González-Juanatey JR; González A. Actividad de sistemas y mediadores neurohormonales como causa de hipertensión arterial. Rev Lat Cardiol 2002;23:163-71. 80. Cowley AW. Long-term control of arterial blood pressure. Physiol Rev 1992:72:231-300 81. Rodriguez-Artalejo F; Banegas JR; Guallar-Castillon P. Epidemiology of Herat failure. Rev Esp Cardiol 2004;57:163-70 82. Hooper L; Bartlett C; Davey SM; Ebrahim S. Reduced dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev.2004;(1):CD003656 83. Neter JE; Stam BE; Kok FJ; Grobbee DE; Geleijnse JM. Influence of weight reduction of pressure: a meta-anal of randomized controlled trials. Hypertension;42:878-84 84. He FJ; MacGregor GA. How far should salt intake be reduced?. Hypertension 2003;42:1093-9 85. Jurgens G; Graudal NA. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholaminas, cholesterols, an triglyceride. Cochrane Database Syst Rev.2004;(1):CD004022 86. He FJ; MacGregor NA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev.2004;(3):CD004937 87. McCarty MF. Marinobufagenin may mediate the impact of salty diets on ventricular hypertrophy by disrupting the protective function coronary microvascular endothelium. Med Hypotheses 2005;64:853-63 88. Gates PE; Takana H; Hiatt WR; Seals DR. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004;44:35

89. Wall SM; Kim YH; Stamley L; Glapion DM; Everett LA; Green ED; Verlander LW. NaCl restriction upregulates renal Slc26a4 through subcellular redistribution. Hypertension 2004;44:982 90. Law MR, Frost CD, Wald NJ. By how muchdoes dietary salt reduction lower blood pressure? I. Analysis of observational data among populations. II. Analysis of observational data within populations. III. Analysis of data from trials of salt reduction. Br Med J 1991;302: 811-824 91. Stamler J, Rose G, Elliot P et al. Findings of the international cooperative INTERSALT Study. Hypertension 1991;17 (Supl I): I-9-I-15. 92. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997; 658 (Sup 1): 643S-651S 93. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure: a metaanalysis of randomized controlled trials. JAMA 1996; 275: 1.590-1.597. 94. Stamler J. The Intersalt Study. Am J Clin Nutr 1997; 65 (Supl): 626S-642S. 95. Weinberger MH. Salt sensivity of blood pressure in humans. Hypertension 1996; 27: 481-490. 96. Weinberger MH, Fineberg NS. Sodium and volume sensivity of blood pressure. Age and pressure change over time. Hypertension 1991; 18: 67-71. 97. Intersalt Cooperative Research Group. INTERSALT: an international study of electrolyte excrection and blood pressure: results for 24 hour urinary sodium and potassium excretion. BMJ 1988;297:319-28. 98. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I. Analysis of observational data among populations. BMJ 1991;302:811-5. 99. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence on overweight people with high-normal blood pressure: the trials of hypertension prevention, phase II. Arch Inter Med 1997;157:657-67. 100. Saks FM, Svetkey LP, Vollmer WM, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10. 101. Luft FC, Weinberger MH. Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. Am J Clin Nutr 1997;65:612S-7S. 102. Vollmer WM, Sacks FM, Ard J, Appel L, Bray GA, Simons-Morton DG, et al. for de DASH-Sodium Trial Collaborative Research Group. Effects of Diet and sodium Intake on Blood Pressure: subgroup analysis of the DASH-Sodium Trial. Ann Intern Med 200135:1019-28. 103. McCarron DA. DASH-sodium trial: where are the data? Am J Hipertens 2003;16:92-4 104. Jones DW: Dietary Sodium and Blood Pressure. Hypertension 2004;43:932-35 105. Egan BM. Reproducibility of BP responses to changes in dietary salt. Compelling evidence for universal sodium restriction?. Hypertension 2003;42:457

106. Fernández-Llama P, Poch E, Oriola J, Botey A, De la Sierra A, Revert L et al. Polimorfismos genéticos del sistema renina-angiotensina e hipertensión arterial esencial. Med Clin (Barc) 1999;112: 561-64 107. Muntzel M; Drueke T. A compresive review of the SALT and blood pressure relationship. Am J Hypertens 1992;5:1S-42 108. Kawasaki T, Delea CS, Bartter FC, Smith H. The effect of high-sodium and intakes on blood pressure and other related variables in human subjects with idiopatic hypertension. Am J Med 1978;64:193-8 109. Pamies E; Vallejo I; Carneado J. Factores geneticos en la hipertensión arterial. Hipertensión 2003;20:163-70 110. Guzman-Olivares B; Poch E; Gonzalez-Nuñez D; Larrouse M; Rivera F; de la Sierra A. Polimorfismo G534A del gen 11B-hidroxiesteroide dehidrogenasa tipo-2 y sensibilidad a la sal en la hipertensión arterial esencial. Hipertensión 2004;21:174-78 111. Redon J; Giner V. Genetica de la hipertension arterial. Rev Lat Cardiol 2002;23:136-43 112. Calhoum DA; Oparil S. High blood pressure in women. J Fertil Womens Med 1997;42:198-205 113. Gonzalez-Juanatey JR; Palma JL. Hipertensión arterial en la mujer. Castro Beiras A, editor. Enfermedades cardiovasculares en la mujer. Barcelona:Masson 2000:123-43 114. Weinberger MH. SALT sensitivity of blood pressure in humans. Hypertension 1996 (2ªpt):481-90 115. De la Sierra A; Coca A. Hipertensión arterial y sensibilidad a la sal. Cuadernos latinoamericanos de hipertensión. Vol III. Ed Doyma 1999:27-46 116. Minutolo R, de Nicola L, Zamboli P, Chiodini P, Signoriello G, Toderico C, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46(1):18-25. 117. Larrouse M; Bragulat E; Segarra M; Sierra C; Coca A; de la Sierra A. Increased levels of atherosclerosis markes in SALT-sensitive hypertension. Hypertens 2006;19:87-93 118. Gerts E; Lund-Johansen P; Omvik P. Reproducibility of salt sensitivity using a dietary approach in essential hypertension. J Hum Hypertens 1999;13:375-84 119. Schmidlin O; Forman A; Tanaka M; et al. NaCl-induced renl vasoconstriction in salt-sensitive Africans Americans. Hypertension 1999;33:633-39 120. Chiolero A; Maillar M; Nussberger; et al. Proximal sodium reabsortion. Hypertension 2000 ;36 :631-37 121. Van Paassen P ; de Zeeuw D ; de Long PE ; Navis G. Renin inhibition improves pressure natriusesis in essential hypertension. J Am Soc Nephrol 2000 ;11 :1813-18 122. Miyajima E ; Yamada Y. Reduced sympatic inhibition in salt-sensitive Japanese young adults. Am J Hypertens 1999;12:1195-200 123. Okuguchi T; Osanai T; Kamada T; et al. Significance of sympathetic nervous systen in sodium-induced nocturnal hypertension. J Hypertens 1999;13:947-57

124.Campese VM; Tawadrous M; Bigazzi R. Salt intake and plasma atrial natruretic peptide and nitric oxide in hypertension. Hypertension 1996;28:335-40 125. Siffert W; Diising R. Sodium-proton exchange and primary hypertension. Hypertension 1995;26:649-55 126. Bragulat E; de la Sierra A; Antonio MT; Coca A. Endotelial dysfunction in salt sensitive hypertension. Hypertension 2001;37:444-48 127.Centelles J; Esteban C; Imperial S. Oxido nitrico. OFFARM 2004;23 128. Suzuki M; Mikura Y; Tsushima M; Harano Y. Association of insulin resistance with SALT sensitivity and nocturnal fall in blood pressure. Hypertension 2000;35:864-68 129. Bihorac A; Tezcam H; Özener C: Association between salt sensitivity and target organ damage in essential hypertension. Am J Hypertens 2000;13:864-72 130. Uzu T; Kazembe FS; Ishikawa K;et al. High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension 1996;28:139-42 131. Bertomeu V; Morillas P; Soria F; Mazon P. Ultimas novedades en hipertensión arterial. Rev Esp Cardiol 2006;59:78-86 132. Musiari L; Ceriati R; Taliani U. Early abnormalities of left ventricular diastolic function of sodium-sensitive hypertensive patients. J Hum Hypertens 1999;13:711-16 133. Weinberger MH; Fineberg NS; Fineberg SE; Weinberger M. Salt sensitivity, pulse pressure and death in normal and hypertensive humans. Hypertension 2001;37:429-32 134. Franklin SS; Wachtell K; Papademetriou V; Olsen MH; Devereux RB; Fyhrquist F; et al. Cardiovascular morbidity and mortality in hypertensive patiens with lower higher riks: a LIFE substudy. Hypertension 2005;46:492-9 135. Hunt SC; Geleijnse JM; Wu LL. Enhanced blood pressure response to mild sodium reduction in subjects with 235T variant of the ansiotensinogen gene. J Hypertens 1999;12:460-66 136. Sharma AM; Pischon T; Engeli S; Scholze J. Choice of drug treatement for obesity-releted hypertension: where is wevidence?. J Hypertens;19:667-74 137. Coca A; Dalfo A; Esmatjes E; Listerri JL; Ordoñez J; Gomis R; Gonzalez-Juanatey JR; Martin-Zurro A. Tratamiento y control del riesgo cardiovascular en atención primaria en España. Estudio PREVENCAT. Med Clin 2006;126:201-5 138. Tobian L. SALT and hypertension. Lesson from animal models that relate to human hypertension. Hypertension 1991;17:152-8 139. Stamler J; Cirillo M. Dietary salt and renal stone disease. Lancet 1997;349-506 140. Gelejinse JM; Wirreman JCM; dem Breeijen JH. Dietary electrolyte intake and blood pressure in older subjects. J Hypertens 1996;13:375-84 141. Kurtz TW, Morris RC Jr. Dietary chloride as a determinant of sodium-dependent hypertension. Science 1983;222:1139-41.

142. Whitescarver SA; Ott CE; Jackson BA; et al. Salt-sensitive hypertension : contribution of chloride. Science 1984;223:1430-32 143. Schorr U; Distler A ; Sharma AM. Effect of sosium choride and sodium bicarbonate-rich mineral water on blood pressure and metabolic parameters in elderly normotensive individuals. J Hypertens 1996;14:131-35 144. De Wardener HE. Franz Volhard lecture 1996. Sodium transport inhibitors and hypertension. J Hypertens 1996;14 (Supl 5):S9-S18 145. Guyton AC. Physiologic regulation of arterial pressure. Am J Cardiol 1961;18:401-7 146. Guyton AC. Kidneys and fluids in pressure regulation. Hypertension 1992;19 (Supl 1):12-8 147. Yip KP; Wagner AJ; Marsh DJ. Detection of apical Na/H exchanger activity inhibition in proximal tubules induced by acute hypertension. Am J Phisiol Regul Integr Comp Phisiol 2000;279:1412-18 148. Palmer BF. Im`paired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. Am J Med Sci 2001;321:388-400 149. Moreno C; Maier KG; Hoagland KM: Abnormal pressure natriuresis in hypertension. Am J Hypertens 2001;14:90-7 150. Majid DS; Said KE; Omoro SA; Navar LG. Nitric oxide dependecy of arterial pressure-induced changes in renal intersticial hydrostatic pressure in dogs. Circ Res 2001;88:347-51 151. Harrap SB; Cumming AD; Davies DL; et al. Glomerular hyperfiltration, higt renin, and low-extracellular volume in higt blood pressure. Hypertension 2000;35:952-57 152. Dhal LK; Knudsen KD; Heine M; Leiti G. Effects of chronic excess salt ingestion. J Exp Med 1967;126:687-99 153. Dahl LK; Knudsen KD; Iwai J. Humoral transmission of hypertension. Circ Res 1969;24:121-33 154. Fedorova OV; Kolodkin NI; Agalakova NI; et al. Marinobufagenin, an endogenous a-i Sodium pump ligand, in hypertensive dahl salt-sensitive rats. Hypertension 2001; 37:462-66 155. Aperia A. Regulation of sodium/potassium ATPase activity. Curr Hypertens Rep 2001;3:165-71 156. Manunta P; Hamilton BP; Hamlyn JM. Structure-activity relationships for the hypertensinogenic activity of ouabain. Hypertension 2001;37:472-77 157. Tao QF; Hollenberg NK; Price DA; Graves SW. Sodium pump isoform specificity for the digitalis-like factor isolated from human peritoneal dialysate. Hypertension 1997;29:815-21 158. Oparil S; Zaman MA; Calhoum DA. Pathogenesis of Hypertension. Ann Intern Med 2003;139:761-76 159. Laragh JH. Laragh`lessons in pathophysiology and clinical pearls for treating hypertension. Am Hypertens 2001;14:84-9 160. Sealey JE; Blumenfeld JD; Bell GM; et al. On the renal basis for essential hypertension. J Hypertens 1988;6:763-77 161. Brenner BM; Garcia DL; Anderson S. Glomeruli and blood pressure. Less of one, more the other?. Am

Hypertens 1988;1:335-47 162. Brenner BM; Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 1994;23:171-75 163. Brenner BM; Anderson S. The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J Cardiovas Pharmacol 1992;19 Supl 6:S1-7 164. Brenner BM; Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int 1997;52 Supl 63:S124-7 165. Flaa A; Mundal H; Eide I; Kjeldsen S; Rostrup M.Sympathetic activity and cardiovascular risk factors in young men in the low, normal, and high blood pressure ranges. Hypertension 2006;47:396-402 166. Chodosh J; Morton SC; Mojica W; Maglione M; Suttorp MJ; Hilton L; Rhodes S; Shekelle P. Meta-Analysis: Chronic disease self-management programs for older adults. Ann Intern Med 2005;143:v6 167. Calles-Escadon J; Cipolla M. Diabetes and endotelial dysfunction. Endocr zrev 2001;22:36-52 168. Cosentino F; Lüscher TF. Effects of blood pressure and glucosa on endotelial function. Hypertens Rep 2001;3:79-88 169. Laragh JH. The abnormal plasma renin levels in essential hypertension. Am J Hypertens 2001;14:191 170. Dzurik R; Spustova M; Gajdos M. Nitric oxide modulation of metabolic and haemodynamic balance. Bratisl Lek Listy. 2005;106:252-6 171. Casas JP; Chua W; Loukogeorgakis S; Vallance P; Smeeth L; Hingorani AD; MacAllister RJ. Effects of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes. Lancet 2005;366 172. Navar LG. The kidney in blood pressure regulation and developement of hypertension. Med Clin North Am 1997; 81: 1165-1197. 173. Timmermans PB; Wong PC; Chiu AT; et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993: 45: 205-251. 174. Carey RM; Jin XH; Siragy HM. Role of angiotensin AT receptor in blood pressure regulation and therapeutic implications. Am Hypertens 2001;14:98-102 175. Lozano JV; Redon J; Cea-Calvo L; Fernandez-Perez C; Navarro J; Bonet A; Gonzalez-Esteban J. hipertrofia ventricular izquierda en la población hipertensa española. Estudio RIC-HTA. Rev Esp Cardiol 2006;59:136-42 176. Kosch M; Hausberg M; Westermann G; et al. Alterations of calcium and magnesium content of red cell membranes in patients with primary hypertension. Am Hypertension 2001;14:254-58 177. Cordero A; Laclaustra M; Leon M; Grima A; Casasnovas JA; Luengo E; del Rio A; Ferreira I; Alegria E. Prehypertension is associated with insulin resistance state and not with an inicial renal function impairment. A Metebolic Syndrome in Active Subjects in Spain (MESYAS). Am J Hypertens 2006;19:189-96 178. Steffel J; Lüscher TF; Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006;113:722-31

179.Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserver endotheliun-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994; 330: 1036-1040. 180. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-1474. 181. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997; 30 (Part 1): 405-408. 182. Woods A; Moshang J. Como reducir los riesgos de la diabetes, la hipertension y la enfermedad cardiovascular. Nursing 2006;24:16-20 183. Luengo E; Ordoñez B; Bergua C; Laclaustra M. Obesidad, dislipemia y síndrome metabolico. Rev Esp Cardiol 2006;5:21-9 184. Cordero A; Moreno J; Alegria E. Hipertensión arterial y síndrome metabolico. Rev Esp Cardiol 2006;5:38-45 185. Januszewicz A. The natriuretic peptides in hypertension. Curr Opin Cardiol 1995; 10: 495-500. 186. Zimmerman RS. Hormonal and humeral considerations in hypertension disease. Med Clin North Am 1997; 81: 1213-1229. 187. Banegas JR. Epidemiologia de la situacion arterial en España. Situación actual y perspectivas. Hipertensión 2005;22:353-62 188. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE). J Am Coll Cardiol. 2005;45:712-9. 189. Lubseb J, Wagener G, Kirwan BA, De Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic satable angina and hypertension: the ACTION trial. J Hypertens. 2005;23:641-8. 190. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906. 191. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting-enzime inhibitor or calcium channel blocker versus diurtics. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002; 288:2981-97 192. Burt VL, Whelton P, Rocella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25: 305-13.

193. ECEHA. Estudio Cooperativo Español de Hipertensión Arterial en el Anciano. Primera fase-prevalencia y características de la hipertensión arterial en el anciano en España. Sociedad Española de Geriatría y Gerontología. Liga Española para la Lucha contra la HTA. Sociedad Española de Cardiología. Sociedad Española de Medicina Familiar y Comunitaria. Madrid: Pharma Consult Services, SA. EDIPHARMA; 1996 194. Gabriel Sánchez R, Alonso Arroyo M, Bermejo Pareja F, Muñiz García J, López Rodríguez I, Suárez Fernández C, et al. Proyecto EPICARDIAN: estudio epidemiológico sobre enfermedades y factores de riesgo cardiovasculares en ancianos españoles. Diseño, método y resultados preliminares. Rev Esp Geriatr Gerontol 1996;31:327-34. 195. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systollic hypertension. JAMA 1991; 265:3225-63. 196. Coca A Combination therapy under investigation in large-scale trials: the INVEST study. J Cardiovasc Pharmacol 1999; 34 (Supl 3): S29-S35 197. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 with suspected acute myocardial infarction. Lancet 1995; 345: 669-85 198. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-28 199. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35. 200. The SOLVD Investigadors Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302. 201. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. B M J 1998; 317: 703-713. 202. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2. BMJ 1998; 317: 713-20. 203. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62. 204. Pitt B Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: the losartan Heart Failure Survival Study (ELITE-2). Meeting of the American Heart Association. Atlanta (EE.UU.), 19-22 de noviembre de 1999 205.Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000;18:1465-75 206. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a

randomised trial. Lancet 1999;353:9-13. 207. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7. 208. Brown MJ, Palmer CR, Castaigne A, De Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-action calcium-channel blocker or diuretic in the international Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72. 209. Hanson L, Hedner T, Lund-Johansen P, Kjeldsen S, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65. 210. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini J, Miller M, et al, for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-10. 211. Hanson L, Lindholm LH, Niskamen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertensive: Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6. 212. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41. 213. Dahlöf B, Devereux RB, Kjeldensen SV, Julius S, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003 214. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patientes randomized to doxazosin vs chlorthalidone. JAMA 2000;283:1967-75. 215. De la Sierra A, Ruilope LM, Coca A, Luque-Otero M, en representación del GEDEC (Grupo Español de Estudios Cardiovascular Relación entre el perfil de riesgo cardiovascular y la selección y utilización de los fármacos antihipertensivos. Med Clin (Barc) 2000;115:41-5. 216. S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension 2004;43:10-7. 217. Alderman, MH; Cohen, H; Madhavan, S. Dietary sodium intake and mortality: The National Healthy and Nutrition Examination Survey /NHANES I). Lancet 1998; 351-378. 218. Giner V, Esteban MJ, Forner MJ, Redón J. Tratamiento farmacológico combinado en el manejo de la hipertensión arterial crónica esencial. Hipertensión 2004; 21:139-57 219. Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C, for the Canadian Hipertensión Education Program. The 2004 Canadian recomendations for the management of hipertensión: Part II Therapy. Can J Cardiol 2004; 20:41-54. 220. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S. Guidelines for management of hypertension: report of the fourth working party of British Hypertension Cociety, 2004 BHS

IV. J Hum Hypertens 2004; 18:139-85. 221. Colin PR; Moore TJ; Swartz SL; et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000;36:461-65 222. Myers MG; Asmar R; Leenen FH; Safar M. Fixer low-dose combination therapy in hypertension. J Hypertens 2000;18:317-25 223. Hilleman DE; Ryschon KL; Mohiuddin SM; Wurdeman RL. Fixe-dose combination vs monotherapy in hypertension. J Hum Hypertens 1999;13:477-83 224. Mediavilla JD; Sabio JM; Fernadez-Torres C: Tratamiento de la hipertensión arterial. Med Clin (Barc) 2003;120:108-16 225. Staessen JA; Gasowiski J; Wang JG; et al. Risks of untreated and trreated isolated systolicc hypertension in the elderly. Lancet 2000;355:865-72 226. Kaplan NM. New issues in the treatement of isolated systolic hypertension. Circulation 2000;102:1079-81 227. Forette F; Seux ML; Staessen JA; et al. The prevention of dementia with antihypertensive treatement. New evidence from the Sys-Eur study. Arch Intern Med 2002;162:2046-52 228. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000:183:S1-S22 229. De Swiet M. Maternal blood pressure and birthweight. Lancet 2000;355:81-2 230. Dekker G; Sibai B. Primary, secondary, and tertiary prevention of pre-eclamsia. Lancet 2001;357:209-15 231. Shotan A; Widerhorn J; Hurst A; Elkayan U. Risks of angiotensin-conversin enzyme inhibition during pregnancy. Am J Med 1994;96:451-56 232. Wassertheil-Smoller S; Anderson G; Psaty BM; et al. Hypertension and its treatement in postmenopausal women. Hypertension 2000;36:1007-12 233. Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Reports 2000;2:370-77 234. Appel LJ. Lifestyle modification as a means to prevent and treat high blood pressure. J Am Soc Nephrol 2003;14(7 supl 2):S99-S102 235. Ferreira IJ; Ferreira AI; del Rio A; Casasnovas JA. La alimentación y la actividad fisica en la hipertensión. Rev Lat Cardiol 2002;23:144-51 236. Stamler J, Caggiula AW, Grandits GA. Relation of body mass, and alcohol, nutrient, fiber and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr 1997;65:338S-65 237. Dengel DR; Hagberg JM; Pratley RE; et al. Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercice plus weight loss in obese, hypertensive midi-age men. Metabolism 1998;47:1075-82

238. Marks SJ; Chin S; Strauss BJG;. The metabolic effects of preferential reduction of visceral adiposity in abdominaly obese men. Int Obesity 1998;22:893-98 239. Masuo K; Ogihara T; Tuck ML. Mechanisms in weight loss. Am J Hypertens 2001;14:222A 240. Grassi G; Seravalle G; Colombo M; et al. Body weight reduction, sympatetic nerve traffic, and arterial baroreflex in obese nortensive humans. Circulation 1998;97:2037-42 241. Ogawa Y; Aizawa-Abe M; Masuzaki H; et al. Role of leptin in blood pressure reduction during caloric restriction. J Hypertens 2000;18 Spl 4:S15 242. Perticone F; Ceravolo R; Candigliota M; et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress. Diabetes 2001;50:159-65 243. Jones DW. Body weight and blood pressure. Effects of weight reduction on hypertension. Am J Hypertens 1996; 9: 50-54. 244. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure: a metaanalysis of randomized controlled trials. JAMA 1996; 275: 1.590-1.597. 245. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The trial of study: adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med 1992; 152: 131-136. 246. Church TS; Kampert JB; Gibbons LW; et al. Usefulness of cardiorepiratory fitness as a preddictor of all-cause and cardivascular disease mortality in men wiht systemic hypertension. Am J Cardiol 2001;88:651-56 247. Grassi G; Seravalle G; Calgoun DA; Mancia G. Physical training and baroreceptor control of sympatetic nerve activity in humans. Hypertension 1994;23:294-301 248. Tanaka H; Dinenno FA; Monahan KD; et al. Aging, habitual exercice, and dynamic arterial compliance. Circulation 2000;102:1270-75 249. De Souza CA; Shapiro LF; Clevenger CM; et al. Regular aerobic exercice prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation 2000;1351-57 250. Araujo-Vilar D; Osifo E; Kirk M; et al. Influence of moderate physical exercice on insulim-mediated glucose uptake in healthy subjects. Metabolism 1997;46:203-9 251. Halbert JA, Silagy CA, Finucane P, Withers RT, Hamdorf PA, Andrews GR. The effectiveness of exercise training in lowering blood pressure:a meta-analysis of randomised controlled trials of 4 weeks or longer. J Human Hypertens 1997; 11: 641-49. 252. Leermakers EA; Dunn AL; Blair SN. Exercice management of obesity. Med Clin Nosth Am 2000;84:419-39 253. Mac Mahon S. Alcohol consumption and hypertension. Hypertension 1987; 9:111-121. 254. Medrano MJ; Cerrato E; Boix R; Delgado-Rodriguez M. Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales. Med Clin (Barc) 2005;124:606-12 255. Victor RG, Hansen J. Alcohol and blood pressure-a drink a day. N Engl J Med 1995; 332: 1.782-83.

256. Kaplan N. Hipertension clinica.waverly Hispanica, 4ª edicion.2003:206-36 257. Frezza M, Di Padova C, Pozzato G, Terpin M, Baraona E, Lieber ChS. High blood alcohol levels in women. The role of decreased gastric alhohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990; 322: 95-99. 258. Smith-Warner SA; Spiegelman D; Yaun SS; et al. Alcohol and breast cancer in women. JAMA 1998;100:2-4 259. Pardell H, Armario P, Treserras R, Hernández R. Tabaco, alcohol y obesidad. En: Rodicio JL, Romero JC, Ruilope LM, eds. Tratado de hipertensión. 2.ª ed. Madrid: Fundación para el estudio de las enfermedades cardiovasculares, 1993; 109. 260. Wilson K; Gibson N; Willan A; Cook D. Effect of smoking cessation on mortality after myocardial infarction. Arch Interm Med 2000; 160:939-44 261. Liang YL; Shiel LM; Teede H; et al. Effects of blood pressure, smoking, and their interaction on carotid artery structure and function. Hypertension 2001;37:6-11 262. Lancaster T; Stead L; Sigaly C; Sowden A. Effectiveness of intervention to help people stop smoking: Findings from the Cocchrane Library. BMJ 2000;321:355-58 263. Tanus-Santos JE; Toledo JC; Cittadino M; et al. Cardiovascular effects of transdermal nicotine in midly hypertensive smokers. Am J Hypertens 2001;14:610-14 264. Pardell H; Tresserras R; Salto E; et al. Manegement of the hypertensive patient who smokes. Drugs 1998;56:177-87 265. Harris GD; White RD. Lifestyle modifications for the prevention and treatement of cardiovascular disease: an evidence-based approach. Mo Med 2004;101:222-6 266. De la Figuera M; de la Sierra A; Ruilope LM; Coca A. Prescripcion de las medidas no farmacologicas en el tratamiento de la hipertensión arterial en Atención Primaria 2000;17:137-47 267. Fernandez-Vergel R; Peñarrubia MT; Rispau A; Espin A; Gonzalo L; Pavon F. Seguimos realmente una dieta mediterranea?. Aten Primaria 2006;37:148-53 268. Mediavilla García JD, Sabino Sánchez JM, Fernández-Torres C. Tratamiento de la hipertensión arterial. Med Clin (Barc) 2003;120:108-16. 269. Krousel-Wood MA, Muntner P, Whelton PK. Primary prevention of essential hypertension. Med Clin North Am 2004;99:223-38. 270. Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II. Analysis of observational data within populations. BMJ 1991;302:815-9. 271. Hermansen K. Diet, blood pressure and hipertension. Br J Nutr 2000;83 (supl 1):S113-9. 272. Page LB. Hipertension and atherosclerosis in primitive and acculturating societies. En: Hunt SC, editor. Hypertension update. Bloomfieh Health Learnig Systems 1980;1-12. 273. Hildebrant G, Beudt M, Gutenbrunner C. The effects of sodium-containing mineral water on blood pressure.

Z Phys Med 1986;15:321-7. 274. Shore AC, Markandu ND, McGregor GA. A randomised crossover study to compare the blood pressure response to sodium loading with and without chloride in pacients with essential hypertension. J Hypertens 1988;6:613-7. 275. Luft FC, Zemel MB, Sowers JA, Fineberg NS, Weinberger MH. Sodium bicarbonate and sodium chloride: effects on blood pressure and electrolyte homeostasis in normal and hypertensive man. J Hypertens 1990;8:663-70. 276. Kunes J, Zicha J, Jelinek J. The role of chloride in deoxycorticosterone hipertension. Selective sodium loading by diet or drinking fluid. Physiol Res 2004;53:149-54. 278. De la Sierra A. La restriccion salina es una medida de utilidad en la prevencion y tratamiento de la hipertensension arterial. Hipertensión 2004;21:317-21 279. Bear TC. The bread of the 21st century. Aust J Nutr Diet 1997;54:198-203 280. Ajar I, Kotchen T. Regional variations of blood pressure in the United States are associated with regional variations in dietary intakes: the NHANES-III data. J Nutr 2003;133:211-4. 281. Morikawaq Y, Nakagawa H, Okayama A, Mikawa K, Sakata K, Miura K, et al. A cross-sectional study on association of calcium intake with blood pressure in Japanese population. J Hum Hypertens 2002;16:105-10 282. McCarron DA. Role of adequate dietary calcium intake in the prevention and management of salt-sensitive hypertension. Am J Clin Nutr 1997;65:712S-6S. 283. Espeland MA, Kumanyika S, Yunis C, Zheng B, Brown WM, Jackson S, et al. Electrolyte intake and nonpharmacologic blood pressure control. Ann Epidemiol 2002;12:587-95 284. Whelton PK, He J, Cutler JA, Bracanti FL, Appel lj, Follmann D. Effects of oral potassium on blood pressure. Meta-analysis or randomized controlled clinical trials. JAMA 1997;277:1624-32 285. Dolson GM; Wesson DE; Adrogue HJ. Vascular relaxation probably meediates the antihypertensive effect of a high potassium diet: a role for enhance vascular Na, K-ATAase activity. J Hypertens 1995;13::1433-39 286. Sing H; Linas SL. Potassium therapy of hypertension. Miner Electrolyte Metab 1993;19:57-63 287. Wilson DK; Sica DA; Miller SB. Effects of potassium on blood pressure in salt-sensitive and salt-resistant black adolescents. Hypertension 1999;34:181-86 288. Delgado-Almeida A; Aviv A; Hollenberg NK; Weder A. Reinterpreting Sodium-Potasium data in salt-sensitive hypertension: A prospective debate. Hypertension 2005;45:e4-e5 289. Espeland MA; Kumanyika S; Yunis C; et al. Electrolyte intake and nonpharmacologic blood pressure control. Hypertension 2001;35:864-68 290. Bostick RM; Fosdick L; Grandits GA; et al. Effect of Calcium supplementation on serum Cholesterol and blood pressure. Arch Fam 2000;9:31-39 291. Pan L; Gross KW. Transcripcional regulation of renin. Hypertensyon 2005;54:3